全球臨床次世代定序儀（NGS）領域分析（2024-2030）

Analysis of the Clinical Next-generation Sequencing Sector, Global, 2024-2030

出版日期: 2024年11月08日 | 出版商:

Frost & Sullivan | 英文 71 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

對人工智慧的持續投資將加速資訊解決方案開發並推動變革性成長

Frost & Sullivan 的分析研究了臨床次世代定序儀(NGS) 產業，涵蓋不同類型的產品、工作流程和臨床應用。全球市場預計將在 2024 年至 2030 年期間穩定成長，其中服務和資訊學領域是主要驅動力，實現重要的收益里程碑。 NGS 市場包括端到端工作流程，包括文庫製備、定序以及資料分析和解釋，專為製藥/生物技術和診斷等關鍵最終用戶領域的臨床使用而設計。在這些領域，NGS技術主要用於疾病診斷和監測、伴同性診斷、臨床試驗和患者分層。

該分析評估了推動和限制 NGS 技術在臨床實踐中使用成長的因素，並提供了來自北美、歐洲、亞太地區 (APAC)、拉丁美洲以及中東、非洲和南亞 (MEASA) 的案例研究。。它還透過評估行業細分、法規環境和新興經營模式以及市場收益和預測，揭示了行業帶來的核心成長機會。

成長指標
生長促進因子
成長抑制因素
預測考慮因素
收益預測
按產品分類的收益預測
按工作流程進行收益預測
按用途分類的收益預測
按地區分類的收益預測
收益預測分析
價格趨勢和預測分析
收益佔有率
收益佔有率分析
競爭者
企業應用資訊學解決方案

成長要素：裝備

成長指標
收益預測
按地區分類的收益預測
預測分析

成長要素：工作流程解決方案

成長指標
收益預測
按地區分類的收益預測
預測分析

成長要素：服務

成長指標
收益預測
按地區分類的收益預測
預測分析

成長要素：資訊學

成長指標
收益預測
按地區分類的收益預測
預測分析

臨床次世代定序儀領域的成長機會領域分析

成長機會 1：整合多組體學資料以實現個人化醫療
成長機會2：癌症微小殘留病灶的檢測與治療
成長機會3：單細胞與空間體學在臨床研究的擴展
成長機會 4：亞太地區、中東、非洲和南亞的基因組學計畫和生物資訊學發展

附錄與後續步驟

成長機會的好處和影響
下一步
附件清單
免責聲明

簡介目錄

Product Code: KAE6-55

Continued Investment in AI is Driving Transformational Growth by Accelerating Information Solutions Development

This Frost & Sullivan analysis examines the clinical next-generation sequencing (NGS) industry, covering the different type of products, workflows, and applications for clinical purposes. The global market is projected to grow steadily from 2024 to 2030, achieving significant revenue milestones, driven largely by services and informatics segments. The NGS market encompasses end-to-end workflows, including library preparation, sequencing, and data analysis and interpretation, specifically designed for clinical applications across key end-user segments: pharmaceutical and biotechnology, and diagnostics. Within these sectors, NGS technologies are primarily employed to diagnose and monitor diseases, as well as for companion diagnostics, clinical trials, and patient stratification.

This analysis assesses the factors driving and restraining the growth of the use of NGS technology in clinical settings and offers case studies from North America, Europe, Asia-Pacific (APAC), Latin America, and the Middle East, Africa, and South Asia (MEASA). It also identifies the core growth opportunities that the industry presents by evaluating industry segments, the regulatory environment, and emerging business models, as well as market revenue and forecasts.

Ecosystem

Scope of Analysis
Segmentation

Growth Environment: Transformation in Clinical Next-generation Sequencing

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Clinical Next-generation Sequencing Industry

Ecosystem in Clinical Next-generation Sequencing

Competitive Environment
Key Competitors

Growth Generator in Clinical Next-generation Sequencing

Growth Metrics
Growth Drivers
Growth Restraints
Forecast Considerations
Revenue Forecast
Revenue Forecast by Product
Revenue Forecast by Workflow
Revenue Forecast by Application
Revenue Forecast by Region
Revenue Forecast Analysis
Pricing Trends and Forecast Analysis
Revenue Share
Revenue Share Analysis
Competitive Players
Company Informatics Solutions for Applications

Growth GeneratorInstruments

Growth Metrics
Revenue Forecast
Revenue Forecast by Region
Forecast Analysis

Growth GeneratorWorkflow Solutions

Growth Metrics
Revenue Forecast
Revenue Forecast by Region
Forecast Analysis

Growth GeneratorServices

Growth Metrics
Revenue Forecast
Revenue Forecast by Region
Forecast Analysis

Growth GeneratorInformatics

Growth Metrics
Revenue Forecast
Revenue Forecast by Region
Forecast Analysis

Growth Opportunity Universe Analysis of the Clinical Next-generation Sequencing Sector

Growth Opportunity 1: Integration of Multi-omics Data for Personalized Medicine
Growth Opportunity 2: Minimal Residual Disease Detection and Treatment in Cancer
Growth Opportunity 3: Expansion of Single-cell and Spatial Omics in Clinical Research
Growth Opportunity 4: Genomics Initiatives and Bioinformatics Development in APAC and MEASA